Of note, these tumor therapy effects triggered by anti‐PD‐L2 were abolished when lacking CD8+ T cells, suggesting that CD8+ cells are downstream effector cells of anti‐PD‐L2. The gene discussed is PDCD1LG2; the disease is neoplasm.